Published: 4 March 2024
Author(s): Jiaxing Tan, Rongxin Yang, Liyin Xiao, Yuanlin Xia, Wei Qin
Issue: May 2024
Section: Original Article

Immunoglobulin A nephropathy (IgAN), considered the most prevalent form of primary glomerular disease worldwide, is characterized by the deposition of IgA in the mesangial area of the glomeruli and exhibits substantial clinicopathological heterogeneity [1]. Presently, the primary therapeutic approaches for IgAN patients involve supportive care, mainly included Angiotensin-Converting Enzyme Inhibitors (ACEI) or Angiotensin II Receptor Blockers (ARB), along with other symptomatic treatments, glucocorticoid therapy, and immunosuppressive therapy [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.